Tech Company Financing Transactions
BlueWillow Biologics Funding Round
On 7/8/2009, BlueWillow Biologics landed $10 million in Series B funding from Perseus.
Transaction Overview
Company Name
Announced On
7/8/2009
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Series B
Investors
Perseus (Norman Selby)
Proceeds Purpose
The funding will support the advancement of numerous clinical and preclinical programs, including the development of products for herpes labialis, onychomycosis, acne, and cystic fibrosis as well as intranasal vaccines for seasonal influenza and other diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2311 Green Rd.
Ann Arbor, MI 48105
USA
Ann Arbor, MI 48105
USA
Phone
Website
Email Address
Not Recorded
Overview
BlueWillow Biologics is a privately-held biopharmaceutical company focused on developing and commercializing intranasal vaccines, based on its patented nanotechnology platform.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Peralta
VP - Bus. Development
David Muth
VP - R & D
Ali Fattom
Browse more venture capital transactions:
Prev: 7/8/2009: PlanarMag venture capital transaction
Next: 7/8/2009: Control4 venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to record funding rounds that are announced publicly. VC investment data records on this site are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs